SCHEMBL9904218

SCHEMBL9904218

Fc1cccc(F)c1-c1ccc2[nH]nc(Br)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 11/20 0.46
PIM3 Q86V86 10/20 0.46
PIM2 Q9P1W9 10/20 0.46
DYRK1A Q13627 4/20 0.42
PRKD3 O94806 2/20 0.42
MAP4K4 O95819 2/20 0.42
CDK2 P24941 2/20 0.42
MARK3 P27448 2/20 0.42
FLT4 P35916 2/20 0.42
MAPK9 P45984 2/20 0.42
CLK2 P49760 2/20 0.42
MAP4K2 Q12851 2/20 0.42
CAMK2B Q13554 2/20 0.42
CAMK2G Q13555 2/20 0.42
MARK2 Q7KZI7 2/20 0.42
MINK1 Q8N4C8 2/20 0.42
HIPK4 Q8NE63 2/20 0.42
AURKB Q96GD4 2/20 0.42
SLK Q9H2G2 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904321 0.81 PIM1 (0.46) PIM1PIM3PIM2DYRK1APRKD3
SCHEMBL5514710 0.79 MKNK1 (0.63) PIM1PIM3PIM2DYRK1APRKD3
SCHEMBL31391692 0.79 CYP1A2 (0.44) DYRK1APRKD3MAP4K4CDK2MARK3
SCHEMBL11904166 0.75 ITK (0.46) DYRK1APRKD3MAP4K4CDK2MARK3
SCHEMBL29468189 0.75 ITK (0.46) DYRK1APRKD3MAP4K4CDK2MARK3
SCHEMBL16025560 0.74 NTRK1 (0.39) DYRK1AMAP4K4CDK2MARK3CLK2
SCHEMBL9904674 0.72 PIM1 (0.47) PIM1PIM3PIM2TRPA1ALOX5AP
SCHEMBL29361220 0.71 PDPK1 (0.38) DYRK1APRKD3MAP4K4CDK2MARK3
SCHEMBL14738214 0.71 PDPK1 (0.38) DYRK1APRKD3MAP4K4CDK2MARK3
SCHEMBL30855645 0.71 PDPK1 (0.68) PIM1DYRK1APRKD3MAP4K4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM3 3/4885PIM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.